Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr. Lal PathLabsNSE:LALPATHLAB -0.21%93 Net Margin % is 21.25% as of Jun. 2026, which is 27% above its 10-year median of 16.75. GuruFocus rates NSE:LALPATHLAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,735.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Dr. Lal PathLabs ranks better than 90.64% on this metric.
The historical rank and industry rank for Dr. Lal PathLabs's Net Margin % or its related term are showing as below:
NSE:LALPATHLAB'
s Net Margin % Range Over the Past 10 Years
Min: 11.84 Med: 16.75 Max: 19.79
Current: 18.75
NSE:LALPATHLAB's Net Margin % is ranked better than 90.64% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.85
vs NSE:LALPATHLAB: 18.75
Dr. Lal PathLabs (NSE:LALPATHLAB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Dr. Lal PathLabs Net Margin % Related Terms
Dr. Lal PathLabs Net Margin % Historical Data
* Premium members only.
The historical data trend for Dr. Lal PathLabs's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Net Margin % distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Net Margin % of 21.25% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Dr. Lal PathLabs and its competitors. This is 27% above median its historical median of 16.75. Over the past decade, Dr. Lal PathLabs' Net Margin % has ranged from 11.84 to 19.79. According to the industry distribution chart, Dr. Lal PathLabs ranks #19 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 9.4%.
Is Dr. Lal PathLabs' Net Margin % too high?
Dr. Lal PathLabs' current Net Margin % of 21.25% is 27% above median its 10-year median of 16.75. Over the past 10 years, this metric has ranged from a low of 11.84 to a high of 19.79. Based on the distribution chart, Dr. Lal PathLabs ranks #19 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #19 out of 203 companies for Net Margin %. This places Dr. Lal PathLabs in the top 9% of its industry — outperforming the majority of peers. Historically, Dr. Lal PathLabs' own Net Margin % has ranged from 11.84 to 19.79 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Dr. Lal PathLabs and its competitors. Dr. Lal PathLabs's current Net Margin % is 21.25%, which is 27% above median its own 10-year median of 16.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current Net Margin % is 21.25%, which is 27% above median its 10-year median of 16.75. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Net Margin % is 21.25% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
Net Margin %: 21.25% (27% above median its 10-year median of 16.75)
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
